Entrepreneurs' Organization had seven of its members give TED-style talks on April 25. Ammar Selo

Moving the needle on something — whether it's changing the world or growing your business — hearing how others accomplished their own goals can be a beacon of hope and guidance for others.

The local Entrepreneurs' Organization chapter, EO Houston, hosted a series of seven TED Talk-style talks by members of the organization. These seven entrepreneurs discussed everything from being an introvert in a world of extroverts to the biggest security threat to American citizens: obesity. EO Talks took place at a breakfast event on April 25 at Houston Baptist University. If you missed the event, check out these overheard quotes from the day of discussions.

“When you get people involved in your organization, your job (as CEO) is alignment. Keep your team aligned with the strategic objectives of your company.”

— Paul Sarvadi, chairman, CEO and co-founder of Insperity, in his talk, "Take Care of Your People: An Entrepreneur's Journey." Connectivity is key, says Sarvadi.

“Taking care of your people is not rocket science. In fact, rocket science would be easier. It involves math and science — it works the same every day. But as soon as you put people in the mix, what worked yesterday might not work today.”

— Sarvadi continued in his talk about the importance of human resources in the the work place.

“What if everyone in the world knew what they stood for — imagine what that world would look like. We would know how we fit. We would be the best versions of ourselves. And, the world would be the best version of itself.”

— Winnie Hart, founder of TwinEngine in her talk, "What Do You Stand For?" Hart discussed finding one's identity and motivators — both in business and in life.

“Everywhere we look introverts are living in an extroverted world. It’s natural if you’re an introvert, like me, to feel a little insecure or that you feel the need to compete with your extraverted friends.”

— Darlene Gagnon, CEO and co-founder of Kinnect Global Management Services in her talk, "The Introverted Entrepreneur Competing in an Extroverted World." Gagnon says that introverts on track to be the most successful entrepreneurs with their execution skills, detail oriented nature, and ability to tune out the noise.

“It is the men in our lives that need to take action. Gentlemen, stand with us. Help us create a better presence so that we can sustain a future.”

— Shoshi Kaganovsky, CEO and founder of SensoLeak Global, in her talk, "Women Entrepreneurs—To Be..Or..To Be The Best." Kaganovsky compared how people say, "behind every great man is a woman," to how female leaders also need the support from the other gender.

“Entrepreneurship is an endless circle of reinventing yourself, being able to change, and keeping a positive attitude while doing so.”

— Kaganovsky continued in her talk as advice to the room of entrepreneurs.

“We can escape this crushing threat we call obesity. How are you going to make your escape?”

— Dr. Joe Galati, liver disease expert, radio host and author in his talk, "America's #1 National Security Threat." Galati argued that it's not Russia or North Korea that pose a major threat to the United States — it's our own health issues caused by obesity.

“We’ve all heard of the term ‘side hustle.' Maybe my dad invented the ‘side hustle.’”

— Chris Hotze, CEO and founder of Crescere Capital, in his talk, "Understanding the Power of Recurring Revenue." Hotze tells the story of how his father created a residential real estate side business out of necessity, and how that entrepreneurialism affected his own business career.

“As entrepreneurs, as long as we see control, we visualize an opportunity far greater than we see the risk.”

— Ali Nasser, CEO of AltruVista in his talk, "The Entrepreneur's Opportunity Cost," Nasser explains how entrepreneurs are hesitant to put money in the stock market, yet dive into ownership and risks for their own businesses.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.